^
Association details:
| Biomarker: | EGFR mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Immunotherapy + Angiogenesis inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Immunotherapy strategies for EGFR-mutated advanced NSCLC after EGFR tyrosine-kinase inhibitors failure
Published date:
10/23/2023
Excerpt:
NSCLC patients with positive EGFR mutations after EGFR-TKIs failure received subsequent immunotherapy plus anti-angiogenesis and chemotherapy are likely to have more benefits in ORR, DCR and mPFS...
Secondary therapy:
Chemotherapy
DOI:
10.3389/fonc.2023.1265236
Source:
Title:
The efficacy and safety of immune checkpoint inhibitors for patients with EGFR-mutated non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy: A systematic review and network meta-analysis
Published date:
08/16/2023
Excerpt:
ICIs+Chemo+Antiangio brings the greatest survival benefit in NSCLC patients with EGFR mutations who progressed on EGFR-TKI therapy, even for whom with baseline brain metastases.
Secondary therapy:
Chemotherapy
DOI:
https://doi.org/10.1002/cam4.6453
Source:
Title:
Immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: A systematic review
Published date:
07/18/2023
Excerpt:
We performed a systematic review on efficacy of ICI-based strategies in EGFR-mutant NSCLC according to most updated evidence….the combination of ICI with antiangiogenic and chemotherapy showed promising results.
Secondary therapy:
Chemotherapy
DOI:
https://doi.org/10.1016/j.ctrv.2023.102602
